ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called ABL001 taken in combination with dasatinib
(Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic
Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in
lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute
Lymphoblastic Leukemia (Ph+ ALL).
It is expected that 25-34 people will take part in this research study.
- ABL001
- Dasatinib (Sprycel®)
- Prednisone